Infections

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Communicable Diseases

Papillomavirus Infections

Congenital Abnormalities

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Virus Diseases

DNA Virus Infections

Tumor Virus Infections

Genital Diseases

Urogenital Diseases

Disease Attributes

All Drugs and Chemicals

Vaccines

Registry, survey, and HPV status data from 2004-2006

Registry, survey, and HPV status data from 2011-2012

Medical Director

This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.

Time perspective: The study will be conducted using data collected both retrospectively/concurrently from registries and prospectively by questionnaire survey.

Baseline survey data were collected during a prior study from 2004-2005.

Safety Monitoring: An expert panel on teratology consisting of one teratologist from each of the participating countries will review all available medical records related to any congenital anomalies to search for any emerging patterns that may be indicative of an association between GARDASIL™ exposure in the mother and the subsequent congenital anomalies in the babies.

GARDASIL™ Vaccine Impact in Population Study (V501-033)

GARDASIL™ Vaccine Impact in Population Study

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Denmark was recorded. Incidence rates are for all age groups and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Denmark was recorded. Incidence rates are for women \<=26 years of age and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Denmark was recorded. Incidence rates are for women \>26 years of age and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Norway was recorded. Incidence rates are for all age groups and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Norway was recorded. Incidence rates are for women \<=26 years of age and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Norway was recorded. Incidence rates are for women \>26 years of age were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Sweden was recorded. Incidence rates are for all age groups and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Sweden was recorded. Incidence rates are for women \<=26 years of age and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. The collection of such data in these registries is mandated by law and compliance is generally very high. The number of new cases of high-grade (2/3) CIN registered during the assessment periods in Sweden was recorded. Incidence rates are for women \>26 years of age and were age-adjusted using the European Standard Population. The incidence before Gardasil licensure is an average over the 3-year period.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. In addition, lesional tissue samples were routinely collected and stored; the 2004 to 2006 period was chosen because it was sufficiently recent to reflect HPV type status immediately before licensure of Gardasil. The number of new cases of HPV 6/11/16/18-related high-grade (2/3) CIN was estimated based on the proportion of HPV 6/11/16/18 in all CIN in a representative sample. Incidence was age-adjusted according to Nordic Standard Population.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. In addition, lesional tissue samples were routinely collected and stored; the 2004 to 2006 period was chosen because it was sufficiently recent to reflect HPV type status immediately before licensure of Gardasil. The percentage of new cases of high-grade (2/3) CIN related to high-risk HPV types other than 16 and 18 was analyzed. High-risk HPV types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Incidence was age-adjusted according to Nordic Standard Population.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. In addition, lesional tissue samples were routinely collected and stored; the 2004 to 2006 period was chosen because it was sufficiently recent to reflect HPV type status immediately before licensure of Gardasil. The number of new cases of HPV 6/11/16/18-related cervical cancer was estimated based on the proportion of HPV 6/11/16/18 in all cervical cancers in a representative sample. Incidence was age-adjusted according to Nordic Standard Population.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. In addition, lesional tissue samples were routinely collected and stored; the 2004 to 2006 period was chosen because it was sufficiently recent to reflect HPV type status immediately before licensure of Gardasil. The percentage of new cases of cervical cancer associated with high-risk HPV types other than 16 and 18 was estimated based on the proportion of HPV 16/18 in all cervical cancer in a representative sample. Incidence was age-adjusted according to Nordic Standard Population.

The incidence of HPV-related histologically confirmed female genital diseases, including vulvar and vaginal cancer and their high-grade precursors was to be assessed.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. In addition, lesional tissue samples were routinely collected and stored; the 2004 to 2006 period was chosen because it was sufficiently recent to reflect HPV type status immediately before licensure of Gardasil. The percentage of liquid-based cervical cytology samples positive for HPV 6, 11, 16, or 18 was analyzed.

All Nordic countries participating in this study have national cervical cancer screening programs and registry systems that routinely collect information on cervical cytology, histology, and/or definitive therapy results. In addition, lesional tissue samples were routinely collected and stored; the 2004 to 2006 period was chosen because it was sufficiently recent to reflect HPV type status immediately before licensure of Gardasil. The percentage of liquid-based cervical cytology samples positive for high-risk HPV Types other than 16 or 18, and not co-infected with Types 16 or 18, was analyzed.

The percentage of live born babies with major congenital anomalies (MCA) born to women vaccinated with Gardasil during pregnancy and to women in the general population was assessed. For Denmark and Sweden diagnoses of congenital anomaly within 1 year of birth are included; for Norway diagnoses at birth are included.

The incidence of CIN by Gardasil vaccination status was to be assessed.

The incidence of other cervical cancers by Gardasil vaccination status was to be assessed.

The incidence of other HPV-related genital diseases, including vulvar and vaginal cancers, by Gardasil vaccination status was to be assessed.

The percentage of participants with liquid-based cervical cytology samples positive for HPV 6, 11, 16, and 18 was to be analyzed by Gardasil vaccination status.

Danish Cancer Society

Union for International Cancer Control

Cancer Registry of Norway

Karolinska Institutet

Merck Sharp & Dohme LLC

Per protocol, adverse events were not collected as part of the study database; therefore, none were collected and the number at risk is zero

Denmark Participants

Norway Participants

Sweden Participants

Participants in Denmark who completed the first survey (before licensure of GARDASIL)

Participants in Norway who completed the first survey (before licensure of GARDASIL)

Participants in Sweden who completed the first survey (before licensure of GARDASIL)

Total

Age, Continuous

Sex: Female, Male

Participants who took the first survey given before Gardasil licensure

Senior Vice President, Global Clinical Development

Denmark Participants 2004 to 2006 Before Gardasil Licensure

Denmark Participants 2007, After Gardasil Licensure

Denmark Participants 2008 After Gardasil Licensure

Denmark Participants 2009 After Gardasil Licensure

Denmark Participants 2010 After Gardasil Licensure

Denmark Participants 2011 After Gardasil Licensure

The analysis population was the entire population of qualifying women in Denmark and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia (CIN) for Participants of All Ages in Denmark

The analysis population was the entire population of qualifying women \<=26 years of age in Denmark and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants <=26 Years of Age in Denmark

The analysis population was the entire population of qualifying women \>26 years of age in Denmark and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants >26 Years of Age in Denmark

Norway Participants 2004 to 2006 Before Gardasil Licensure

Norway Participants 2007, After Gardasil Licensure

Norway Participants 2008 After Gardasil Licensure

Norway Participants 2009 After Gardasil Licensure

Norway Participants 2010 After Gardasil Licensure

Norway Participants 2011 After Gardasil Licensure

The analysis population was the entire population of qualifying women in Norway and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants of All Ages in Norway

The analysis population was the entire population of qualifying women \<=26 years of age in Norway and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants <=26 Years of Age in Norway

The analysis population was the entire population of women \>26 years of age in Norway and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants >26 Years of Age in Norway

Sweden Participants 2004 to 2006 Before Gardasil Licensure

Sweden Participants 2007, After Gardasil Licensure

Sweden Participants 2008 After Gardasil Licensure

Sweden Participants 2009 After Gardasil Licensure

Sweden Participants 2010 After Gardasil Licensure

Sweden Participants 2011 After Gardasil Licensure

The analysis population was the entire population of qualifying women in Sweden and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants of All Ages in Sweden

The analysis population was the entire population of qualifying women \<=26 years of age in Sweden and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants <=26 Years of Age in Sweden

The analysis population was the entire population of qualifying women \>26 years of age in Sweden and thus changed throughout the analysis. The number of participants analyzed given below is an estimate calculated from the number of reported cases and the incidence data.

Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia for Participants >26 Years of Age in Sweden

Overall CIN

HPV 6/11/16/18-related CIN

Denmark Participants 2011 to 2012 After Gardasil Licensure

Norway Participants 2011 to 2012 After Gardasil Licensure

Sweden Participants 2011 to 2012 After Gardasil Licensure

The analysis population was participants of all ages with newly-diagnosed high-grade CIN and lesional tissue samples analyzed for HPV types

Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Cervical Intraepithelial Neoplasia for Participants of All Ages

The analysis population was participants \<=26 years of age with newly-diagnosed high-grade CIN and lesional tissue samples analyzed for HPV types

Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia for Participants <=26 Years of Age

The analysis population was participants \>26 years of age with newly-diagnosed high-grade CIN and lesional tissue samples analyzed for HPV types

Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia for Participants >26 Years of Age

CIN not related to HPV 16/18

Incidence of Cervical Intraepithelial Neoplasia Associated With High-risk HPV Types Other Than 16/18 in Participants <=26 Years of Age

Incidence of Cervical Intraepithelial Neoplasia Associated With High-risk HPV Types Other Than 16/18 in Participants >26 Years of Age

Overall cervical cancer

HPV 6/11/16/18-related cervical cancer

The analysis population was participants with newly-diagnosed cervical cancer and lesional tissue samples analyzed for HPV types

Incidence of HPV 6/11/16/18-related Cervical Cancer in Participants of All Ages

The analysis population was participants \<=26 years of age with newly-diagnosed cervical cancer and lesional tissue samples analyzed for HPV types

Incidence of HPV 6/11/16/18-related Cervical Cancer in Participants <=26 Years of Age

The analysis population was participants \>26 years of age with newly-diagnosed cervical cancer and lesional tissue samples analyzed for HPV types

Incidence of HPV 6/11/16/18-related Cervical Cancer in Participants >26 Years of Age

Cervical cancer not related to HPV 16/18

Incidence of Cervical Cancer Associated With High-risk HPV Types Other Than 16/18 in Participants <=26 Years of Age

Incidence of Cervical Cancer Associated With High-risk HPV Types Other Than 16/18 in Participants >26 Years of Age

Analysis of this endpoint was not planned nor were the data collected. Thus, the number of participants analyzed is zero.

Incidence of HPV-related Histologically Confirmed Female Genital Diseases, Including Vulvar and Vaginal Cancer and Their High-grade Precursors

The analysis population was participants \<=26 years of age with liquid-based cytology samples analyzed for HPV types

Prevalence of HPV 6/11/16/18 Infection in Participants <=26 Years of Age

The analysis population was participants \>26 years of age with liquid-based cytology samples analyzed for HPV types

Prevalence of HPV 6/11/16/18 Infection in Participants >26 Years of Age

Prevalence of HPV Infection for High-risk Types Other Than 16/18 for Participants <=26 Years of Age

Prevalence of HPV Infection for High-risk Types Other Than 16/18 for Participants >26 Years of Age

Live babies born between 2007 and 2011 to Denmark participants who received Gardasil during pregnancy

Babies Born to Denmark Participants Who Received Gardasil

Live babies born between 2007 and 2011 to Denmark participants in the general population, including participants who did and did not receive Gardasil

Babies Born to Denmark Participants

Live babies born between 2007 and 2011 to Norway participants who received Gardasil during pregnancy

Babies Born to Norway Participants Who Received Gardasil

Live babies born between 2007 and 2011 to Norway participants in the general population, including participants who did and did not receive Gardasil

Babies Born to Norway Participants

Live babies born between 2007 and 2011 to Sweden participants who received Gardasil during pregnancy

Babies Born to Sweden Participants Who Received Gardasil

Live babies born between 2007 and 2011 to Sweden participants in the general population, including participants who did and did not received Gardasil

Babies Born to Sweden Participants

The analysis population represents the babies born to participating mothers, instead of female participants, because the number of babies represents the denominator for the percentage calculation, not female participants (i.e., mothers)

Percentage of Live Born Babies With a Major Congenital Anomaly

Denmark participants who received Gardasil on or before March 2012

Denmark Participants Who Received Gardasil

Denmark Participants Who Did Not Receive Gardasil

Norway participants who received Gardasil on or before March 2012

Norway Participants Who Received Gardasil

Norway Participants Who Did Not Receive Gardasil

Sweden participants who received Gardasil on or before March 2012

Sweden Participants Who Received Gardasil

Sweden Participants Who Did Not Receive Gardasil

The analysis population was to be women who underwent cervical screening. A joint decision was made by the study team to forgo the stratified analysis by vaccination status because there were few women who had both been vaccinated with Gardasil and undergone cervical cancer screening. Thus, the number of participants analyzed is zero.

Incidence of Cervical Intraepithelial Neoplasia by Gardasil Vaccination Status

Incidence of Cervical Cancer by Gardasil Vaccination Status

Incidence of Other HPV-related Genital Diseases by Gardasil Vaccination Status

Prevalence of HPV 6, 11, 16, and 18 Infection by Gardasil Vaccination Status

Overall Study

Neoplasms

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Two doses of Cecolin® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose

Two doses of Cecolin® given at 0 and 12 months with blood draw at baseline, prior to second dose and one-month post second dose

Two doses of Cecolin® given at 0 and 24 months with blood draw at baseline, prior to second dose and one-month post second dose

Two doses of Gardasil® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose

One dose of Gardasil® at 0 months and one dose of Cecolin® at 24 months with blood draw at baseline, prior to second dose and one-month post second dose.

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

Cecolin®

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine

Gardasil®

This planned randomized controlled trial will evaluate a bivalent HPV vaccine, Cecolin®, in alternate 2-dose regimens, compared to an established HPV vaccine. Gardasil® used as the comparator vaccine, as this vaccine is most widely used in low- and low-middle income countries.

This randomized, active-comparator controlled, open-label study will enroll total of approximately 1025 girls aged 9 to 14 years, in one country in Africa (Ghana) and one country in South/Southeast Asia (Bangladesh). Subjects will be randomized 1:1:1:1:1 to receive Cecolin® at 0 and 6 months, 0 and 12 months, or 0 and 24 months, Gardasil® at 0 and 6 months, or Gardasil® at 0 months and Cecolin® at 24 months. For each arm, blood will be collected for immunologic testing at baseline and one month following second dose. Additional blood collections will occur immediately prior to the administration of the second dose, as well as at additional later time points, for immunobridging to other published and ongoing trials. The study also aims to evaluate the performance of a mixed arm (group 5) of Gardasil® followed by Cecolin® and collect data on effects of interchangeability.

Girls of target age will be identified, and their parents contacted to attend an informational session for individual discussion, informed consent, assent and randomization.

The study will be conducted by the research groups in icddr,b in Bangladesh and Malaria Research Center (MRC) in Ghana.

Phase 3 Trial of a Bivalent HPV Vaccine (Cecolin®) in Young Girls

Phase 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity & Safety of Alternate 2-Dose Regimens of Cecolin® Compared to Gardasil® in 9-14 Year-Old Girls in Low and Low-Middle Income Countries

HPV IgG GMC by ELISA and GMT by PBNA at baseline, at the time of second dose, and one month after the second dose (for immunologic bridging and kinetic modeling)

HPV IgG GMC by ELISA following a single dose of Gardasil® or Cecolin® at 6, 12, and 24 months

Anti-HPV 16 and 18 IgG antibody geometric mean concentration (GMC), measured by enzyme-linked immunosorbent assay (ELISA) one month after the second dose for the 0, 6-month arms, for the 0, 12-month arm or for the 0, 24-month arm following vaccination

Anti-HPV 16 and 18 serum neutralizing antibody geometric mean titer measured by PBNA compared to ELISA at all time points (in a representative subset)

Seroconversion rate, defined as a 4-fold rise in anti-HPV 16 and 18 IgG antibody as measured by ELISA, at baseline and one month following the last dose

Anti-HPV16 and 18 IgG antibody GMC measured by ELISA one month following the last dose of the Gardasil® 0-6 month two dose regimen and the Gardasil®-Cecolin® 0-24 month two dose regimen

Anti-HPV16 and 18 IgG antibody GMC measured by ELISA 24 months following the first dose of the Gardasil® 0-6 month two dose regimen and the Cecolin® 0-6 month two dose regimen

Number of subjects in each study arm reporting solicited local and systemic adverse events

Number of subjects in each study arm reporting unsolicited adverse events

Number of subjects in each study arm reporting serious adverse events

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
GARDASIL™ Vaccine Impact in Population Study (V501-033)	NCT01077856	Human Papilloma...		18 Years - 45 Years	Merck Sharp & Dohme LLC
Phase 3 Trial of a Bivalent HPV Vaccine (Cecolin®) in Young Girls	NCT04508309	Cervical Cancer	Cecolin® Gardasil®	9 Years - 14 Years	PATH
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	NCT04425291	Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS	4-valent HPV Va... 9-valent HPV Va... GARDASIL®	20 Years - 45 Years	Shanghai Bovax Biotechnology Co., Ltd.
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years	NCT04921111	HPV Infection V...	SCT1000 Gardasil®9 placebo Gardasil®	18 Years - 45 Years	Sinocelltech Ltd.
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years	NCT04921111	HPV Infection V...	SCT1000 Gardasil®9 placebo Gardasil®	18 Years - 45 Years	Sinocelltech Ltd.
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	NCT04422366	Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS	9-valent Human ... GARDASIL®	20 Years - 45 Years	Shanghai Bovax Biotechnology Co., Ltd.

Spots Global Cancer Trial Database for gardasil®

Every month we try and update this database with for gardasil® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for gardasil®

Every month we try and update this database with for gardasil® cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for gardasil® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.